Clinical Trials Browser

Phase 2 × elotuzumab × 30 days × Clear all

NCT02420860 2026-04-15

Elotuzumab and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT02719613 2026-04-15

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Completed

Multiple Myeloma

NCT04835129 2026-03-27

IMPEDE

Phase 2 Active not recruiting

Multiple Myeloma